President Donald Trump revealed a groundbreaking deal with pharmaceutical giants Eli Lilly and Novo Nordisk to dramatically reduce prices on popular weight-loss medications, promising affordability for millions.
The agreement will expand Medicare coverage for these obesity drugs, enabling more seniors to access essential treatments for the first time.
Patients can expect their out-of-pocket costs for drugs like Wegovy and Zepbound to drop to between $149 and $350 per month, a significant decrease from previous prohibitive pricing.
The announcement took a dramatic turn during a press conference when Novo Nordisk executive Gordon Findlay collapsed, drawing attention to the event and Trump's reaction.
Despite the optimistic rollout, health experts expressed concerns about the long-term effectiveness of these medications, cautioning that many patients regain weight after stopping treatment.
Critics and health advocates raised skepticism about whether these price cuts adequately address the broader challenges surrounding obesity treatment, adding complexity to the narrative of this ambitious healthcare initiative.
Top Keywords
Donald Trump/Gordon Findlay/Dr. Oz/Robert F. Kennedy Jr./Dr. Jon LaPook/Dr. Céline Gounder/Dr. Holly Lofton/Washington, United States/Eli Lilly/Novo Nordisk/Medicare/Centers for Medicare and Medicaid Services/
99
